Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

IMS 2023 | B-PRISM: Phase II trial of Dara-VRd in high-risk smoldering multiple myeloma

Omar Nadeem • 28 Sep 2023

IMS 2023

Rare Diseases Smoldering Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide

B-PRISM

Omar Nadeem, MD, Dana-Farber Cancer Institute, Boston, MA, summarizes the positive results of the B-PRISM study (NCT04775550), which is evaluating the safety and efficacy of daratumumab, bortezomib, lenalidomide and dexamethasone (Dara-VRd) in patients with high-risk smoldering multiple myeloma (HR-SMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisory boards: Janssen, BMS, Takeda, Sanofi, GPCR Therapeutics, GSK

Early interception in SMM & novel agents being explored

Irene Ghobrial et al. • 25 Mar 2024

Dara-RVD, with an MRD-adaptive duration of therapy, in high-risk smoldering myeloma

Omar Nadeem • 10 Dec 2023

Investigating bispecific antibodies in high-risk smoldering myeloma: the ImmunoPRISM platform study

Omar Nadeem • 10 Dec 2023

The value of bispecifics in myeloma & the importance of optimally sequencing immunotherapies

Omar Nadeem • 28 Sep 2023

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Hematological manifestations associated with primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024